Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Hormontherapie in der Peri- und Postmenopause und Malignomrisiko

Hormone therapy in the perimenopause and postmenopause and cancer risk

  • 247 Accesses

Zusammenfassung

Die Hormontherapie (HT) mit Sexualsteroiden wird in der Peri- und Postmenopause häufig zur Linderung postmenopausaler Symptome eingesetzt. Ein mögliches Tumorwachstum gehört zu den Bedenken der Patientinnen und Ärzte, die eine HT erwägen. Viele Karzinomerkrankungen des weiblichen Genitaltraktes und der Mamma sind hormonabhängig. Bekannt ist, dass die Dauer und Höhe der Östrogenexposition bei der Frau mit dem Mammakarzinomrisiko korreliert. Andererseits ist die Therapie mit Östrogenrezeptorblockern und Aromataseinhibitoren hoch wirksam in Therapie und Prophylaxe von Mammakarzinomen. Im Folgenden sollen die relevanten bekannten Veränderungen verschiedener Malignomrisiken durch Sexualsteroide dargestellt werden. Eine detaillierte Bewertung der gesamten Evidenz zu dieser Thematik ist auch der S3-Leitlinie Hormontherapie in Peri-und Postmenopause zu entnehmen.

Abstract

Hormone therapy (HT) with sex steroids in perimenopausal and postmenopausal women is often used for relief of postmenopausal symptoms. A possible tumor growth is one of the concerns of physicians and patients who are considering HT. Many malignant diseases of the female genital tract and breasts are hormone-dependent. It is known that the duration and amount of estrogen exposure in women correlates with the risk of breast cancer. On the other hand treatment with estrogen receptor blockers and aromatase inhibitors is highly effective in the treatment and prevention of breast cancer. In this article the known relevant changes of various cancer risks due to sex steroids are presented. A detailed assessment of the overall evidence on this issue is given in the S3 guidelines on hormone therapy in perimenopausal and postmenopausal women.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 12(6):668–678

  2. 2.

    Greiser CM, Greiser EM, Doren M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 11(6):561–573

  3. 3.

    Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92(11):2049–2058

  4. 4.

    Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11(6):545–560

  5. 5.

    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

  6. 6.

    Bakken K, Fournier A, Lund E et al (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European prospective investigation into cancer and nutrition. Int J Cancer 128(1):144–156

  7. 7.

    Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2009) Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27(31):5138–5143

  8. 8.

    Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587

  9. 9.

    Chlebowski RT, Anderson GL, Gass M et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684–1692

  10. 10.

    Prentice RL, Chlebowski RT, Stefanick ML et al (2008) Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol 167(12):1407–1415

  11. 11.

    Beral V, Reeves G, Bull D, Green J (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4):296–305

  12. 12.

    LaCroix AZ, Chlebowski RT, Manson JE et al (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305(13):1305–1314

  13. 13.

    Jordan VC, Ford LG (2011) Paradoxical clinical effect of estrogen on breast cancer risk: a „new“ biology of estrogen-induced apoptosis. Cancer Prev Res 4(5):633–637

  14. 14.

    Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430

  15. 15.

    Reding KW, Doody DR, McTiernan A et al (2011) Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat 126(3):749–761

  16. 16.

    Green PK, Weiss NS, McKnight B et al (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7(6):575–580

  17. 17.

    Ortmann O, König K (2005) Hormontherapie im Klimakterium und in der Postmenopause. Dtsch Arztebl International 102(3):144

  18. 18.

    Hulley S, Furberg C, Barrett-Connor E et al (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):58–66

  19. 19.

    Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551

  20. 20.

    Jaakkola S, Lyytinen HK, Dyba T et al (2011) Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 128(7):1644–1651

  21. 21.

    Lacey JV Jr, Brinton LA, Leitzmann MF et al (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405

  22. 22.

    Greiser CM, Greiser EM, Doren M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5):453–463

  23. 23.

    Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710

  24. 24.

    Pearce CL, Chung K, Pike MC, Wu AH (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115(3):531–539

  25. 25.

    Morch LS, Lokkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305

  26. 26.

    Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22(8):1075–1084

  27. 27.

    Chlebowski RT, Schwartz AG, Wakelee H et al (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374(9697):1243–1251

  28. 28.

    Chlebowski RT, Anderson GL, Manson JE et al (2010) Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst 102(18):1413–1421

  29. 29.

    Slatore CG, Chien JW, Au DH et al (2010) Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 28(9):1540–1546

  30. 30.

    Oh SW, Myung SK, Park JY et al (2010) Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health 19(2):279–288

  31. 31.

    Clague J, Reynolds P, Sullivan-Halley J et al (2011) Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev 20(3):560–564

  32. 32.

    McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201–1207

  33. 33.

    Zervoudakis A, Strickler HD, Park Y et al (2011) Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst 103(10):826–834

  34. 34.

    La Vecchia C, Gallus S, Fernandez E (2005) Hormone replacement therapy and colorectal cancer: an update. J Br Menopause Soc 11(4):166–172

  35. 35.

    Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106(5):574–582

  36. 36.

    Chan JA, Meyerhardt JA, Chan AT et al (2006) Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 24(36):5680–5686

  37. 37.

    Slattery ML, Ballard-Barbash R, Edwards S et al (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14(1):75–84

  38. 38.

    Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004

  39. 39.

    Ritenbaugh C, Stanford JL, Wu L et al (2008) Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 17(10):2609–2618

  40. 40.

    Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition. Int J Cancer 128(8):1881–1889

  41. 41.

    Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: S3-Leitlinie „Hormontherapie in der Peri- und Postmenopause“. http://www.dggg.de/fileadmin/public_docs/Leitlinien/2-1-4-ht-lang-hp.pdf,

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.

Author information

Correspondence to Dr. C. Lattrich.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lattrich, C., Schüler, S. & Ortmann, O. Hormontherapie in der Peri- und Postmenopause und Malignomrisiko. Gynäkologe 46, 155–159 (2013). https://doi.org/10.1007/s00129-012-3067-9

Download citation

Schlüsselwörter

  • Mammakarzinom
  • Ovarialkarzinom
  • Bronchialkarzinom
  • Sexualsteroide
  • Kolorektales Karzinom

Keywords

  • Breast cancer
  • Ovarian cancer
  • Lung cancer
  • Sex steroid hormones
  • Colorectal cancer